ERBB2 and neoplasm: The anti-tumor efficacy of these engineered CAR-T cells was evaluated in a mouse model of MC38-HER2 colon adenocarcinoma, where the tumor microenvironment was established through tumor inoculation followed by sublethal lymphodepletion via irradiation (49).